Beyfortus cuts RSV hospitalizations by 82% in babies, RWE shows

Sanofi’s (Euronext: SAN) Beyfortus (nirsevimab) reduced respiratory syncytial virus (RSV) hospitalizations by 82% in infants under six months of age, compared to babies who received no RSV intervention, according to the interim results of an ongoing study published in The Lancet.

Beyfortus, a long-acting antibody provided directly to newborns and infants as a single dose has been approved for use in the European Union, the USA, China, Japan, and many other countries around the world.

"The scale and speed of impact seen after Beyfortus’ introduction demonstrates the strength of all-infant immunization strategies against RSV in babies"These results, from the first RSV season after Beyfortus’ introduction, are part of the three-year NIRSE-GAL study conducted in Galicia, Spain under a collaboration between the provincial government and Sanofi.